Table 3.

Hazard ratios of use of statin and fibrate for risk of cardiovascular disease in Chinese type 2 diabetic patients

Exposures	HR	95%CI	P value
In the entire cohort§†
Use of statins during follow-up	0.66	0.50 to 0.88	.0038
Use of fibrates during follow-up	0.61	0.37 to 1.03	.0640
In the sub-cohort with LDL-C < 3.0 mmol/L¶, §
Use of statins during follow-up	1.10	0.56 to 2.16	.7798
Use of fibrates during follow-up	0.34	0.12 to 1.00	.0495
In the sub-cohort with LDL-C ≥ 3.0 mmol/L¶, §
Use of statins during follow-up	0.60	0.44 to 0.82	.0012
Use of fibrates during follow-up	0.65	0.35 to 1.19	.1590
In the sub-cohort with HDL-C < 1.0 mmol/L in male or 1.3 mmol/L in female ζ, §
Use of statins during follow-up	0.49	0.28 to 0.88	.0162
Use of fibrates during follow-up	0.37	0.13 to 1.09	.0703
In the sub-cohort with HDL-C ≥1.0 mmol/L in male or ≥ 1.3 mmol/L in female ζ, §
Use of statins during follow-up	0.73	0.53 to 1.02	.0662
Use of fibrates during follow-up	0.74	0.41 to 1.35	.3303
In the sub-cohort with metabolic syndrome at baseline ‡,§
Use of statins during follow-up	0.58	0.42 to 0.80	.0010
Use of fibrates during follow-up	0.60	0.35 to 1.05	.0713
In the sub-cohort without metabolic syndrome at baseline ‡,§
Use of statins during follow-up	0.77	0.42 to 1.44	.4201
Use of fibrates during follow-up	0.57	0.12 to 2.73	.4903

†Adjusted for LDL-C (≥ 3.0 mmol/L vs. < 3.0 mmol/L), HDL-C, triglyceride, age, smoking status, duration of diabetes, HbA1c, Ln (ACR + 1), gliclazide and rosiglitazone during follow-up, years of enrolment (selected by the stepwise algorithm with P = .10 for entry and stay);

Adjusted for the variables listed in ‡, except for LDL-C;

ζ, Adjusted for the variables listed in ‡, except for HDL-C;

§, Cox models stratified on deciles of probability of initiation of statin therapy during follow-up and on deciles of probability of initiation of fibrate therapy during follow-up.